Cidara Therapeutics, Inc. (NASDAQ: CDTX) related to its sale to Merck Sharp & Dohme LLC. Under the terms of the proposed transaction, Cidara shareholders will receive $221.50 per share in cash.
Cidara Therapeutics, Inc. (NASDAQ: CDTX) related to its sale to Merck Sharp & Dohme LLC. Under the terms of the proposed transaction, Cidara shareholders will receive $221.50 per share in cash.